Q1 2025 Earnings Call Transcript September 16, 2024 ImmunoPrecise Antibodies Ltd. misses on earnings expectations. Reported ...

全方位治疗性抗体发现公司ImmunoPrecise Antibodies Ltd. (IPA)于2024年7月31日公布了2025财年第一季度财务业绩。公司年度收入略有下降，报告收入5.3百万美元，同比下降7.5%。

LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public ...

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and ...

Good morning, ladies and gentlemen, and thank you for joining us today for ImmunoPrecise Antibodies First Quarter Fiscal Year 2025 Earnings Call. We appreciate your time and interest in our company.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning ...

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract d ...

Despite a year-over-year revenue decline, IPA shows promising growth in key labs and strategic advancements in AI-driven ...

MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11ZUG, Switzerland, September 9, 2024 – MoonLake ...

Proteomic analysis of tunneling nanotubes (TNTs) identifies CD9 and CD81 as major positive regulators of TNT formation.

MinervaX scaling up supply of novel GBS vaccine, ahead of phase III studies Wacker Biotech to manufacture active vaccine protein ingredients and prepare for commercial supply ...